A multisite observational real-world study on the effectiveness of repetitive transcranial magnetic stimulation therapy for patients with treatment-resistant depression in Japan

• DOI: 10.1016/j.psychres.2024.116263
• Publication Date: 2024-11-10T15:27:12Z
• Authors: Yuki Matsuda; Shinsuke Kito; Fumiyo Hiraki; Takuji Izuno; Katsuomi Yoshida; Motoaki Nakamura; Fumitoshi Kodaka; Ryuichi Yamazaki; Nanase Taruishi; Shinichi Imazu; Tetsufumi Kanazawa; Takahiro Mekata; Sotaro Moriyama; Masataka Wada; Shinichiro Nakajima; Kazuyuki Sawada; Shinya Watanabe; Shun Takahashi; Yuuki Toi; Daisuke Hayashi; Shun Igarashi; Ko Fujiyama; Shunichiro Ikeda; Hiroshi Tateishi; Ryohei Kojima; Kengo Sato; Shuken Boku; Minoru Takebayashi; Moritaka Ogura; Atsuhiko Takaya; Kenji Endo; Akira Kita; Hisatoshi Arai; Hisashi Kamimura; Koji Matsuo; Kenzo Denda; Sachi Yamashiro; Daisuke Yoshioka; Junichiro Kizaki; Masaru Mimura; Yoshihiro Noda
• Keywords: Depression

The objective of this study was to reveal the effectiveness repetitive transcranial magnetic stimulation (rTMS) for Japanese patients with treatment-resistant depression (TRD) in clinical practice, based on real-world data from a nationwide multicenter observational Japan. Clinical TRD treated rTMS (NeuroStar TMS treatment system) under public insurance coverage were retrospectively collected 21 institutes between June 2019 and December 2023. Depression severity assessed by 17-item Hamilton Rating Scale (HAMD-17). Response remission defined as ≥50 % reduction baseline ≤7 points HAMD-17, respectively. primary outcome changes HAMD-17 score endpoint following rTMS. Data 497 candidates study. scores (mean (SD)) improved significantly 18.9 (5.3) 9.7 (6.6), response rates at end therapy 53.5 42.8 %, dropout rate due adverse effects 4.2 generally well tolerated. No convulsive seizures or manic observed. These results indicate that conventional is effective safe TRD.